India Launches Rs 4,200 Crore PRIP Scheme to Boost Pharmaceutical and MedTech R&D Innovation
核心洞察
The Department of Pharmaceuticals (搜索) has launched the PRIP (搜索) scheme with a Rs 4,200 crore budget to support research and innovation in pharmaceutical and medical technology sectors.
The program offers Rs 5 crore assistance for early-stage projects led by startups and MSMEs, and up to Rs 100 crore for large-stage projects worth up to Rs 285 crore.
The scheme is expected to support approximately 300 industry and startup research projects, attracting total investment of about Rs 11,000 crore in new medicines, complex generics, biosimilars (搜索) and novel medical devices.
The Department of Pharmaceuticals (搜索) (DoP) has officially launched the Promotion of Research and Innovation in Pharma-MedTech (PRIP (搜索)) scheme, marking a significant milestone in India's efforts to strengthen its pharmaceutical and medical technology sectors. The comprehensive initiative comes with a substantial budgetary allocation of Rs 4,200 crore, designed to accelerate research and development across critical healthcare domains.
Funding Structure and Project Categories
The PRIP (搜索) scheme establishes a tiered funding approach based on Technology Readiness Level (TRL) classifications. Early-stage projects led by startups and MSMEs can access financial assistance of Rs 5 crore for initiatives valued at Rs 9 crore. For more advanced developments, the scheme provides up to Rs 100 crore in assistance for large-stage projects worth up to Rs 285 crore.
The program targets diverse pharmaceutical areas including new chemical entities (搜索), complex generics including biosimilars (搜索), medical devices, stem cell therapy, orphan drugs (搜索), and antimicrobial resistance (搜索) research. In the medical technology sector, eligible projects encompass diagnostics and screening devices using genetic technologies, robotic devices for surgical procedures, and novel in-vitro diagnostics (IVDs) with biomarker-based tests for precision medicine.
Investment Impact and Project Scope
According to DoP projections, the newly launched research incentive scheme is estimated to support nearly 300 industry and startup research projects. This comprehensive support is expected to attract a total investment of approximately Rs 11,000 crore in new medicines, complex generics, biosimilars (搜索) and novel medical devices, demonstrating the scheme's potential for significant economic impact.
Implementation Framework and Payment Structure
Selected projects will receive funding through four milestone-linked installments distributed across stages M0 to M4, excluding M3. Applicants must provide detailed disclosure of how disbursed payments will be utilized, ensuring transparency and accountability in fund allocation.
The scheme incorporates a benefit-sharing mechanism tied to commercialization success. For small projects, applicants are required to share five percent of net sales from each commercialized output annually, with payments ending once total contributions equal the financial assistance received. Large-stage projects face a higher benefit-share requirement of 10 percent of net sales from commercialized outputs, with obligations discharged once 150 percent of the total financial assistance is recovered.
Regulatory Timeline and Application Process
While the scheme was initially announced in 2023, the official rollout of Component B, specifically aimed at promoting new drug and device development, faced delays as the department incorporated industry feedback and implemented several revisions. The Ministry of Chemicals and Fertilizers (搜索) has now notified amendments along with a revised detailed guidance document outlining the scheme's operational framework.
The application deadline is set for November 10, 2025, providing industry participants with a defined timeline for proposal submission. A technical committee will review project proposals and submit recommendations for consideration of additional or follow-on financial assistance, ensuring rigorous evaluation of potential investments.
This initiative represents India's strategic commitment to enhancing its position in global pharmaceutical and medical technology markets while addressing critical healthcare needs through targeted research and development support.